PMID-33888596 – NMN Increases Muscle Insulin Sensitivity in Prediabetic Women
Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, Sindelar M, Yokoyama T, Imai SI. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229.
Quick Reference
| Property | Value |
|---|---|
| PMID | 33888596 |
| DOI | 10.1126/science.abe9985 |
| Year | 2021 |
| Journal | Science |
| Study Type | RCT |
| Evidence Level | II |
| Sample | 25 postmenopausal prediabetic overweight/obese women, 10 weeks |
| Peptide(s) Studied | NAD+ |
Key Findings
- NMN 250 mg/day significantly increased muscle insulin-stimulated glucose disposal compared to placebo
- Upregulated insulin signaling markers (pAkt, pTOR) in skeletal muscle biopsies
- First human RCT demonstrating metabolic benefits of NMN supplementation, published in Science
Study Design
Randomized, double-blind, placebo-controlled trial in 25 postmenopausal women with prediabetes (BMI 25-40). Participants received NMN 250 mg/day or placebo orally for 10 weeks. Primary outcome was muscle insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp with stable isotope tracers and skeletal muscle biopsies.
Limitations
- Small sample size (n=25)
- Limited to postmenopausal women; findings may not generalize to men or younger populations
Clinical Relevance
Provides the first rigorous human evidence that boosting NAD+ via NMN supplementation can improve insulin sensitivity in a clinically relevant population, supporting NAD+ precursor use in metabolic dysfunction.
Related
#research #RCT #evidence-level-II